Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
2017
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
2013
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
2011
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Stem-Cell-like Properties and Epithelial Plasticity Arise as Stable Traits after Transient Twist1 Activation
2015
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
2017
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
2015
EGFR associated expression profiles vary with breast tumor subtype
2007
Routine Clinical Mutation Profiling of Non–Small Cell Lung Cancer Using Next-Generation Sequencing
2015
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
2009
Cell mechanics and the cytoskeleton
2010 StandoutNature
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
2012
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
Hepatocellular carcinoma
2016 Standout
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK)
2010
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
2011
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Mediastinal Lymph Node Dissection versus Mediastinal Lymph Node Sampling for Early Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2014
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Lung Cancer
2008 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Surgical management of oligometastatic non-small cell lung cancer
2016
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD
2005
Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery
2013
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
2018
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
2013
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
2012
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
2015
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
Significance, detection and markers of disseminated breast cancer cells
2006
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
2006
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Gemcitabine in locally advanced and/or metastatic bladder cancer
2000
Advances in the Treatment of Malignant Pleural Mesothelioma
1999
Combinations of Bevacizumab With Cancer Immunotherapy
2018
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
2001
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
2015
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
2017
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013
Immunity, Inflammation, and Cancer
2010 Standout
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
2014
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer
2015
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
2014
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
2011
The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non–Small Cell Lung Cancer
2017
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)
2012
Emerging Biological Principles of Metastasis
2017 Standout
EMT: 2016
2016 Standout
Metastasectomy for Synchronous Solitary Non-Small Cell Lung Cancer Metastases
2014
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
2013
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
2015
Microtubules as a target for anticancer drugs
2004 Standout
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
2007
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
2000
Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma
2017
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
1999
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
2007
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2015
Neutrophils in cancer: neutral no more
2016 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
The PI3K Pathway in Human Disease
2017 Standout
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
2012
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy
2016
Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
2000
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
2002
Tumor Angiogenesis
2008 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
2007
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807)
2003
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI
2016
Suitability of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Specimens for Subtyping and Genotyping of Non–Small Cell Lung Cancer
2012
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
2006
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
2009
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Hepatocellular Carcinoma
2019 Standout
Chemotherapy for advanced non-small cell lung cancer in the elderly population
2015
Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer
2010
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
2009
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
2000
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non–Small Cell Lung Cancer
2006
Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer
2008
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
2014
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Smoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status
2006
Targeted therapies in control of EMT in carcinoma and fibrosis
2007
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
2014
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
2006
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
2009
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.
2002
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
2010
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
2015
Comprehensive Geriatric Assessment for Older Patients With Cancer
2007
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
2018
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
2013
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
2010
The cardenolide UNBS1450 is able to deactivate nuclear factor κB–mediated cytoprotective effects in human non–small cell lung cancer cells
2006
Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10
2007
Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
2017
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
2000
Multiple Myeloma
2011 Standout
Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801
2009
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
2013
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
2014
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
2006
USE OF SILICONE STENTS IN THE MANAGEMENT OF TRACHEOBRONCHIAL STENOSIS DUE TO TUBERCULOSIS
2005
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
2005
Works of Cesare Gridelli being referenced
The Use of Bisphosphonates in Elderly Cancer Patients
2007
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
2004
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
2012
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
2006
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
2011
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population
2009
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial
1996
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
1998
Biological Prognostic and Predictive Factors in Lung Cancer
2009
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
2014
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
2013
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
2003
The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial
2010
Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial
2007
Second-Line Treatment of Advanced Non-small Cell Lung Cancer
2008
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
1999
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
2011
Cetuximab in advanced non-small cell lung cancer
2006
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
1999
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines
2011
Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer
1992
ALK inhibitors and advanced non-small cell lung cancer (Review)
2014
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
2005
Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
2014
Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
2013
Non-small-cell lung cancer
2015
Lung cancer in the elderly
1997
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
2013
Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
2010
The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial
2009
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
2013
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
2004
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents
2003
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
2012
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
2017
Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer
2005
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
2015
Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer
2002
Treatment of advanced non-small-cell lung cancer in the elderly
2009
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC
2006
Treatment of advanced non small cell lung cancer.
2011
Lung Cancer in the Elderly
2007
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
57 Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study
1997
Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.
2003
Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2007
Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study
2005
Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?
2004
Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens
2010
Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay.
2000
Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial
1998
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2009
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
2007
The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
2001
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
2009
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
2012
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
2012
Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy
2009
Mitomycin C and Vindesine: An Ineffective Combination Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
1992
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
2015
Has lung cancer in the elderly different characteristics at presentation?
2002
Evaluation of Changes in Renal Function in a Phase III Study of Maintenance (Mtc) Pemetrexed (Pem) Plus Best Supportive Care (Bsc) Versus Placebo (Plb) Plus Bsc After Induction Treatment (Tx) with Pem Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer (Paramount)
2014